Elan is way down and I’m buying
The drug maker has plunged 60% on concerns about test results for one drug and two patient illnesses linked to another. The damage is way too deep, which means a buying opportunity.
The drug maker has plunged 60% on concerns about test results for one drug and two patient illnesses linked to another. The damage is way too deep, which means a buying opportunity.
You must be logged in to post a comment.